MKI67 and pancreatic neuroendocrine tumor: Case 1: In patient, 51 y.o., male, with MEN 1 syndrome (multiple duodenal and non-functioning pancreatic NETs, operated on chemodectoma, non-functioning adrenal adenoma, persistent PHPT after PTX—2 adenomas removed), long-acting SSA therapy was initiated (Lanreotide 120 mg/28 days) due to multiple pancreatic and duodenal NETs with uncertain malignant potential (with size up to 20 × 24 × 20 mm and Ki-67 2.6%).